Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis

Advances in Therapy

Volumn 28, Issue 1, 2011, Pages 51-61

  Tan, Hiangkiat ^a   Cai, Qian ^a   Agarwal, Sonalee ^b   Stephenson, Judith J ^a   Kamat, Siddhesh ^a  

^a HEALTHCORE INC   (United States)

^b BIOGEN   (United States)

Author keywords

adherence; clinical and economic impact; disease modifying therapies; multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; ECONOMIC EVALUATION; FEMALE; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; RECURRENCE RISK; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ADULT; FEMALE; HEALTH CARE COSTS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; PATIENT ADMISSION; PEPTIDES; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 79952534788     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0093-7     Document Type: Article

References (28)

1. National Multiple Sclerosis Society [online]. 1. Available from URL: http://www.nationalmssociety.org/about-multiple-sclerosis. Accessed March 5, 2010.
2. E.M. Frohman 2003 Multiple sclerosis Med Clin North Am. 87 867 868ix 10.1016/S0025-7125(03)00008-7 12834152 (Pubitemid 36712843)
3. O. Kantarci D. Wingerchuk 2006 Epidemiology and natural history of multiple sclerosis: new insights Curr Opin Neurol 19 248 254 10.1097/01.wco.0000227033.47458.82 16702830 (Pubitemid 43804678)
4. D.S. Goodin E.M. Frohman G.P. Garmany Jr., et al. 2002 Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology 58 169 178 1:STN:280: DC%2BD38%2FnvV2htw%3D%3D 11805241 (Pubitemid 34086933)
5. F. Lubin M. Baier G. Cutter 2003 Effect of relapses on development of residual deficit in multiple sclerosis Neurology 61 1528 1532 (Pubitemid 37505574)
6. L. Osterberg T. Blaschke 2005 Adherence to medication N Engl J Med 353 487 497 1:CAS:528:DC%2BD2MXntVCisL0%3D 10.1056/NEJMra050100 16079372 (Pubitemid 41127293)
7. D.C. Mohr D.E. Goodkin L. Masuoka, et al. 1999 Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis Mult Scler 5 192 197 1:STN:280: DyaK1MzjsFajtw%3D%3D 10408720 (Pubitemid 29290449)
8. A.P. Ross 2008 Tolerability, adherence, and patient outcomes Neurology 71 S21 S23 10.1212/WNL.0b013e31818f3dcb 19064871
9. R.M. Ruggieri N. Settipani L. Viviano, et al. 2003 Long-term interferon-beta treatment for multiple sclerosis Neurol Sci 24 361 364 1:STN:280:DC%2BD2c%2FhvFWjtw%3D%3D 10.1007/s10072-003-0190-3 14716534 (Pubitemid 38029025)
10. F. Patti 2010 Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence Patient Prefer Adherence 4 1 9 10.2147/PPA.S8230 20165593
11. H.L. Tremlett J. Oger 2003 Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS Neurology 61 551 554 12939437 (Pubitemid 37025380)
12. G. Comi 2009 Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta Clin Ther 31 1142 1157 10.1016/j.clinthera.2009. 06.007 19695384
13. P. Flachenecker P. Rieckmann 2003 Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs 63 1525 1533 10.2165/00003495-200363150-00001 12887260 (Pubitemid 36976136)
14. S.E. Andrade K.H. Kahler F. Frech K.A. Chan 2006 Methods for evaluation of medication adherence and persistence using automated databases Pharmacoepidemiol Drug Saf 15 565 574 10.1002/pds.1230 16514590 (Pubitemid 44336271)
15. J.A. Cramer A. Roy A. Burrell, et al. 2008 Medication compliance and persistence: terminology and definitions Value Health 11 44 47 18237359 (Pubitemid 351160875)
16. J. Castelli-Haley M. Oleen-Burkey M.J. Lage K.P. Johnson 2008 Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients Adv Ther 25 658 673 10.1007/s12325-008-0077-z 18641926
17. J. Castelli-Haley M.A. Oleen-Burkey M.J. Lage K.P. Johnson 2009 Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis Adv Ther 26 552 562 1:CAS:528:DC%2BD1MXntVSqsb8%3D 10.1007/s12325-009-0028-3 19444392
18. D.A. Ollendorf E. Jilinskaia M. Oleen-Burkey 2002 Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population J Manag Care Pharm 8 469 476 14740608
19. D.A. Ollendorf J. Castelli-Haley M. Oleen-Burkey 2008 Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis J Neurosci Nurs 40 281 290 10.1097/01376517-200810000-00006 18856249
20. S.C. Steinberg R.J. Faris C.F. Chang, et al. 2010 Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study Clin Drug Investig 30 89 100 1:CAS:528: DC%2BC3cXislSrtrc%3D 10.2165/11533330-000000000-00000 20067327
21. D.L. Roter J.A. Hall R. Merisca B. Nordstrom D. Cretin B. Svarstad 1998 Effectiveness of interventions to improve patient compliance: a meta-analysis Med Care 36 1138 1161 1:STN:280:DyaK1cznt1aqsQ%3D%3D 10.1097/00005650-199808000- 00004 9708588 (Pubitemid 128456406)
22. T. Klauer U.K. Zettl 2008 Compliance, adherence, and the treatment of multiple sclerosis J Neurol 255 Suppl.6 87 92 10.1007/s00415-008-6016-8 19300966
23. P.B. Ginsburg B.C. Strunk M.I. Banker J.P. Cookson 2006 Tracking health care costs: continued stability but at high rates in 2005 Health Aff (Millwood) 25 w486 w495 10.1377/hlthaff.25.w486 (Pubitemid 44871693)
24. D.W. Brandes T. Callender E. Lathi S. O'Leary 2009 A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events Curr Med Res Opin 25 77 92 1:CAS:528:DC%2BD1MXkvFCktrg%3D 10.1185/03007990802569455 19210141
25. K. Costello P. Kennedy J. Scanzillo 2008 Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term Medscape J Med 10 225 19008986
26. K. Treadaway G. Cutter A. Salter, et al. 2009 Factors that influence adherence with disease-modifying therapy in MS J Neurol 256 568 576 10.1007/s00415-009-0096-y 19444532
27. H. Tan J. Yu D. Tabby J. Singer 2009 Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study Mult Scler 16 956 963 10.1177/1352458510373487
28. S.D. Saini P. Schoenfeld K. Kaulback M.C. Dubinsky 2009 Effect of medication dosing frequency on adherence in chronic diseases Am J Manag Care 15 e22 33 19514806